Foley Hoag LLP represented Alcyone Therapeutics (Alcyone) in the negotiation of a license and collaboration agreement with Biogen Inc. (Nasdaq: BIIB) to develop Alcyone’s ThecaFlex DRx™ System, an implantable medical device for intrathecal drug delivery. Biogen will pay $10 million up front and Alcyone is eligible for up to $41 million in potential milestone payments.
Through this agreement, Biogen aims to leverage the ThecaFlex DRx™ System with a goal of improving the patient treatment experience and accessibility for a broader population of people suffering from neurological disorders, such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).
Alcyone is a biotechnology company pioneering next-generation precision gene-based therapies for complex neurological conditions. The company integrates innovation in neuroscience, precision dosing platforms, and manufacturing capabilities to deliver transformative therapies to patients.
Foley Hoag attorneys
Sarah Cooleybeck,
Mark Potash and Annie Li represented Alcyone in the transaction, with assistance from
Jeffrey Quillen, Nicola Lemay, Areta Kupchyk,
Alison Bauer and
Luciano Racco.
